Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
If you were in TCR's editorial offices, surrounded by boxes of articles about acetylcholinesterase inhibitors (AChEI’s), you would quickly develop a sinking sensation. Not because the articles are so boring (though, in fact, they are); rather, because the pharmaceutical hype-sters are back on parade once again.
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.